Company news

Cytokinetics, Incorporated news in 2024

Cytokinetics, Incorporated's news releases, calls and decks from 2024, newest first.

View company

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

December 22, 2024

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

December 19, 2024

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

December 2, 2024

Cytokinetics to Participate in December Investor Conferences

December 1, 2024

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

December 1, 2024

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

November 18, 2024

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

November 15, 2024

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

November 15, 2024

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference

November 11, 2024

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

November 10, 2024

Cytokinetics Reports Third Quarter 2024 Financial Results

November 5, 2024

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024

November 4, 2024

Cytokinetics to Announce Third Quarter Results on November 6, 2024

October 22, 2024

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day

October 15, 2024

Cytokinetics to Host Investor & Analyst Day on October 16, 2024

October 1, 2024

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting

September 29, 2024

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

September 26, 2024

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program

September 23, 2024

Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

September 18, 2024

Cytokinetics Announces Data From Phase 1 Study of CK-4021586

September 8, 2024

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting

September 4, 2024

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

August 31, 2024

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024

August 31, 2024

Cytokinetics Reports Second Quarter 2024 Financial Results

August 7, 2024

Cytokinetics Announces Call for Proposals for Corporate Giving Program

July 29, 2024

Cytokinetics to Announce Second Quarter Results on August 8, 2024

July 24, 2024

Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024

July 15, 2024

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

June 16, 2024

Cytokinetics to Participate in June Investor Conferences

May 28, 2024

Cytokinetics Announces Closing of Public Offering of Common Stock

May 27, 2024

Cytokinetics Announces Proposed Public Offering of Common Stock

May 21, 2024

Cytokinetics Announces Pricing of Public Offering of Common Stock

May 21, 2024

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 21, 2024

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

May 16, 2024

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

May 14, 2024

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

May 12, 2024

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

May 12, 2024

Cytokinetics Reports First Quarter 2024 Financial Results

May 7, 2024

Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

May 7, 2024

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

May 7, 2024

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

April 28, 2024

Cytokinetics to Announce First Quarter Results on May 8, 2024

April 23, 2024

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

April 9, 2024

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

April 4, 2024

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 31, 2024

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

March 24, 2024

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

February 28, 2024

Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials

February 27, 2024

Cytokinetics Reports Fourth Quarter 2023 Financial Results

February 26, 2024

Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

February 12, 2024

Older news releases →

Calls in 2024

Decks in 2024